Table 5.
Characteristics of patients responding to MGCD0103
| Patient number |
|||
|---|---|---|---|
| 1 | 2 | 3 | |
| Age, y | 76 | 52 | 58 |
| Sex | Male | Female | Male |
| Disease | MDS; INT-1 | AML | AML |
| Cytogenetics | Diploid | Complex, 43-46, X, −X, add (3) (q35), +10, t(11;12) (p13;p12) | Diploid |
| Prior treatment | None | Ida + Ara-C; high-dose Ara-C | Decitabine; Ida + Ara-C; Fludara + Ara-C |
| Treatment course | 80 to 60 mg/m2 | 80 to 60 mg/m2 | 60 mg/m2 |
| Time to response | 2 cycles | 2 cycles | 1 cycle |
| Response duration | No repeat aspirate | 3 cycles | 1 cycle |
| On study duration | 4 cycles | 5 cycles | 4 cycles |
| Max HDAC inhibition, %* | 23 | 63 | 38 |
| Max histone acetylation, %* | 149 | 337 | 338 |
*
Inhibition of HDAC activity and histone acetylation were measured in peripheral white cells collected from the patients (“Histone acetylation”).